InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-41.4%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by DRACHMAN JONATHAN G, Chairman & CEO. Director active across 3 companies, notably Neoleukin Therapeutics, Inc.. Cumulatively, 8 filings have been logged. Breakdown: 6 buys · 0 sell. Total volume traded: €2m. Activity tracked since 3 June 2021. The latest transaction was disclosed on 8 March 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations8 total
415 shares0Common StockSEC:0000950170-24-029434:0
5,000 shares0Common StockSEC:0001209191-23-056795:0
200,000 shares@ US$0.859550.0% of flowCommon StockSEC:0000899243-21-044150:0
Ideal exit: 7 Aug 2022 (T+270)
200,000 shares@ US$0.859550.0% of flowCommon StockSEC:0000899243-21-044150
Ideal exit: 7 Aug 2022 (T+270)
100,000 shares@ US$6.11131.2% of flowCommon StockSEC:0001209191-21-053544
Ideal exit: 21 May 2022 (T+270)
100,000 shares@ US$6.11131.2% of flowCommon StockSEC:0001209191-21-053544:0
Ideal exit: 21 May 2022 (T+270)
40,000 shares@ US$9.481818.8% of flowCommon StockSEC:0001209191-21-038690:0
Ideal exit: 28 Feb 2022 (T+270)
40,000 shares@ US$9.481818.8% of flowCommon StockSEC:0001209191-21-038690
Ideal exit: 28 Feb 2022 (T+270)
8 of 8 declarations
About DRACHMAN JONATHAN G
Jonathan G. Drachman is President and CEO of Neoleukin Therapeutics, Inc. and Calithera Biosciences, Inc. He leads these companies with a strategic vision, overseeing all operations and ensuring performance objectives are met. His leadership is crucial for the development of these biopharmaceutical firms.
